|
Scientific Advisory Board
The Scientific Advisory Board (SAB) function provides oversight to operational processes and strategic direction on new opportunities and applications of the Nanotrap® technology.
Dr. Emmanuel Petricoin, III
Dr. Lance Liotta
Dr. Barney Bishop
Dr. Alessandra Luchini
Business Advisory Board
The Ceres Business Advisory Board provides business advice and support to the Ceres Management Team .
Jerry Coughter
Steve Danielson
James DeOlden
Robin A. Felder, Ph.D.
Jennifer Murphy
Klaus Schafer, MD, MPH
Terry Sharrer, Ph.D.
Dr. Emanuel Petricoin, III
Scientific Advisory Board
Dr. Petricoin is one of the inventors of the Nanotrap® technology. As a member of the Ceres Scientific Advisory Board, Dr. Petricoin provides technical guidance and expertise to key components of Ceres Nanosciences' operations. Dr. Petricoin is currently a professor of Life Sciences and serves as the Co-Director of CAPMM Labs at George Mason University. Dr. Petricoin formerly worked with the FDA where he was the senior investigator in the Office of Cell Tissue and Gene Therapies in the Center for Biologics Evaluation and Research. Dr. Petricoin holds a doctorate in microbiology from the University of Maryland at College Park. Together with Dr. Lance Liotta, he has formed the Center for Applied Proteomics and Molecular Medicine. The Center has formed a unique partnership between George Mason and Inova Health System. George Mason University-Inova Health System Translational Research Centers is a joint initiative to coordinate multiple programs to implement proteomics, nanotechnology, and genomics research in cancer, metabolic syndrome, cardiopulmonary diseases, and neurodegenerative and liver diseases. This initiative comprises the research efforts of three shared centers: the Center for Applied Proteomics and Molecular Medicine; the Center for Biomedical Genomics; and the Center for the Study of Genomics of Liver Diseases. Inova and George Mason have combined efforts to recruit internationally renowned scientists, such as Dr. Liotta and Dr. Petricoin, to work closely with clinical investigators from Inova.
|
Dr. Lance Liotta
Scientific Advisory Board
Dr. Liotta is one of the inventors of the Nanotrap® technology. As a member of the Ceres Scientific Advisory Board, Dr. Liotta provides technical guidance and expertise to key components of Ceres Nanosciences' operations. Dr. Liotta is currently a professor of Life Sciences and serves as the Co-Director of CAPMM Labs at George Mason University. He was formerly the Chief of the Laboratory of Pathology at NCI's Center for Cancer Research, where he also served as the chief of the center's Tumor Invasion and Metastases section, Deputy Director for Intramural Research, Co-Director, NCI/FDA Clinical Proteomics Program, and chairs the National Institutes of Health Radiation Safety Committee. He earned his medical degree from Case Western Reserve Medical School and also holds a doctoral degree in biomedical engineering from Case Western Reserve University. Dr. Liotta and Dr. Petricoin began their proteomics collaboration in 1997, which led to the formation of the first Interagency Agreement between NCI and FDA to develop and test technologies for proteomic analysis—the study of protein activity in cells—of cancer and other diseases. Their renowned collaboration has produced more than 100 publications and numerous proteomic processes to develop new methods for diagnosis and treatment of diseases. Combining their clinical and research expertise, they invented a new type of protein microarray technology to simultaneously measure multiple protein pathways from a biopsy specimen. Understanding the activity of protein pathways may ultimately lead to personalized medical treatment and significantly impact public health. In addition to their invention and development of new types of protein microarray technologies, they recently have made several seminal discoveries for biomarker-based research that may assist in the diagnosis of cancer and other diseases.
|
Dr. Barney Bishop
Science Co-Director
As a Director of Science for Ceres, Dr. Bishop provides technical guidance and expertise to key components of the scientific operations of Ceres. This includes oversight of the lab facilities, oversight of the Nanotrap® production, and general support of ongoing lab operations. Dr. Bishop also guides the Research and Development function of Ceres and is a key driver in the development of new applications for the Nanotrap®. Dr. Bishop is currently a professor of General Biology and Protein Biochemistry at George Mason University. Dr. Bishop received a Ph.D. in chemistry from the University of North Carolina at Chapel Hill in 1997, where his graduate research focused on peptide synthesis and engineering. After receiving his doctorate, Dr. Bishop joined the laboratory of Dr. Lynne Regan at Yale University as a postdoctoral associate in order to continue his education and gain experience in the areas of molecular biology, protein engineering and protein biophysical characterization. His research focused on reengineering helical bundle proteins in order to enhance their stability. In the spring of 2001, Dr Bishop joined New River Pharmaceuticals as a Senior Research Scientist. During his time at New River Pharmaceuticals, Dr. Bishop played a major role in the design and assembly of product lead candidates. He joined the Department of Chemistry and Biochemistry at George Mason University in the fall of 2003. His current research interests include molecular engineering, antimicrobial peptides and the design of novel therapeutic agents for combating infection, In 2007, Dr. Bishop joined the scientific advisory board for Kempharm, Inc., an early-phase biopharmaceutical company focused on the development of new and safer treatments for pain, AD/HD and other illnesses.
|
Dr. Alessandra Luchini
Science Co-Director
As a Director of Science for Ceres, Dr. Luchini provides technical guidance and expertise to key components of the scientific operations of Ceres. This includes oversight of the lab facilities, oversight of the Nanotrap® production, and the general support of ongoing lab operations. Dr. Luchini also and supports the Research and Development function of Ceres and is a key driver in the development of new applications for the Nanotrap®. Dr. Luchini is currently a Research Professor at George Mason University. She obtained her doctorate from the University of Padova in Italy in 2005. She has worked as a research fellow for Department of Biotechnology and Bioscience at the University of Milano-Bicocca, in Milano, Italy and as a Teaching Assistant at the University of Milano-Bicocca, Master in Molecular Immunopathology. She has published a number of peer reviewed articles and has been working with CAPMM since 2004. |
Jerry Coughter
Business Advisory Board
Mr. Coughter is the Campus Executive Officer for George Mason University in Loudoun County, Virginia. He previously served as Executive Director of Governor Warner's Biotechnology Commission and was the Industry Director for Biotechnology at Virginia's Center for Innovative Technology, leading the Commonwealth's efforts to grow the industry state-wide. He is a frequent speaker on the roles of universities and state governments in growing technology sectors, including University-centered economic development and innovative models for funding commercialization of new technologies by small businesses. Mr. Coughter has served on SBIR review panels for NSF. He earned a BS in molecular biology at Clemson University, an MS in microbiology & immunology from the Medical College of Virginia Commonwealth University, and an MBA from the Byrd School of Business at Shenandoah University
|
Steve Danielson
Business Advisory Board
Mr. Danielson is a Senior Director, Regulatory Affairs with MedImmune LLC, the biologics unit of AstraZeneca, and has ten years of Regulatory experience in small molecules, biologics and devices. His team shares global regulatory responsibility for the investigational drugs in MedImmune's inflammation, autoimmune and infectious diseases portfolios, all of which are monoclonal antibodies. The portion of the portfolio for which Steve and his team are responsible includes one marketed product, approved and marketed in 62 countries, and several other programs in early and later stages of development, primarily in the autoimmune area. Mr. Danielson holds a B.S. in Organic Chemistry from the Illinois Institute of Technology.
|
James DeOlden
Business Advisory Board
Mr. DeOlden is the president, CEO and founder of Mediatech Inc., a leading manufacturer of life science products for academic and government research institutions, and pharmaceutical corporations. The company employs 150 people, and was named "Biotechnology Company of the Year" in 2004 by the Virginia Biotechnology Association. Mr. DeOlden obtained a B.S. in Microbiology and an M.S. in Biochemistry from CSULB, as well as an MBA from the University of Maryland. He also serves as a board member of the Virginia Biotechnology Association.
|
Robin A. Felder, Ph.D.
Business Advisory Board
Dr. Felder is a Professor of Pathology, Associate Director of Clinical Chemistry at the University of Virginia, as well as Former Director of the Medical Automation Research Center. He received his doctorate from Georgetown University, and continued his post-doctoral training with The National Institutes of Health (NIH) in Bethesda, MD. He conducts basic, clinical and applied research ranging from medical robotics to human hypertension. Dr Felder has spun out 8 companies from the University of Virginia including Medical Automation Systems, Hypogen, WellAWARE Systems, Global Cell Solutions, Ibetics, the Association for Laboratory Automation, and Medical Automation.org.
|
Jennifer Murphy
Business Advisory Board
Jennifer Murphy is the Assistant Vice President for Research and Economic Development and Director of Technology Transfer at George Mason University. She is also the Executive Director of George Mason Intellectual Properties, Inc. (GMIP). Ms. Murphy has been with George Mason for 21 years, 12 of which were as Director of the Office of Sponsored Programs. Prior to joining George Mason University, Ms. Murphy held positions in university administration and sponsored programs at The American University in Washington, D.C. and at Gallaudet University. Ms. Murphy attended the University of Maryland and American University at the undergraduate level and received her MBA from American University in 1982. Ms. Murphy has been a business reviewer for the Civilian Research Defense Fund (CRDF) "Next Steps" program. Ms. Murphy has been actively engaged in a number of professional organizations, in particular the National Grants Management Association (NGMA), The Association of University Technology Managers (AUTM), the Licensing Executive Society (LES), and the Academic Licensing Community of Virginia (ALCOVe).
|
Klaus Schafer, MD, MPH
Business Advisory Board
Dr. Shafer is the President and CEO of TessAraeŽ, a limited liability company founded to develop and commercialize comprehensive differential diagnostic genomic based technology for the detection of infectious disease agents. The company is also helping the industry by developing resequencing tools for more rapid mutation detection in various diseases. Dr. Schafer has previously held positions in the Department of Defense as the Asst. to the Secretary of Defense for Chemical and Biological Defense and as the former Asst. Surgeon General for the U.S. Air Force, where he organized and oversaw the Surgeon General's technology program.
|
Terry Sharrer, Ph.D.
Business Advisory Board
Mr. Sharrer is the director of Innovative Health at INOVA Hospital. He previously held the position of Curator of Health Sciences at the National Museum of American History, Smithsonian Institution, where he worked for 37 years. He received a Ph.D. in history from the University of Maryland, and is the author of three dozen publications about a range of life science subjects. He has been heavily involved in public service, including serving on the boards of the Carillion Biomedical Institute in Roanoke, VA, Immune Deficiency Foundation in Towson, MD, and Inova Fairfax Hospital Cancer Advisory Committee in Fairfax, VA, as well as serving as Chairman of the Board of Directors of the National Foundation for Cancer Research in Bethesda, MD.
|
|
